Product Description
Mechanisms of Action: Potassium Channel Blocker,Sodium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Latvia | Lebanon | Lithuania | Luxembourg | Netherlands | New Zealand | Norway | Poland | Portugal | Romania | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | United Arab Emirates | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Advanz Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Atrial Fibrillation
Phase 3: Atrial Fibrillation|Ventricular Fibrillation|Atrial Flutter|Cardiac Arrhythmias|Stroke|Heart Failure
Phase 2: Atrial Fibrillation|Atrial Flutter|Stroke|Heart Failure|Cardiac Arrhythmias
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| REB20-2257 | P3 |
Not yet recruiting |
Atrial Fibrillation |
2025-01-01 |
|
| RAFF4 Trial | P4 |
Recruiting |
Atrial Fibrillation |
2023-09-30 |
|
| SELECTCARFAP | P4 |
Completed |
Atrial Fibrillation |
2023-06-01 |
|
| MK-6621-049 | N/A |
Completed |
Atrial Fibrillation |
2018-04-05 |